Nektar Therapeutics: Highlights
Financial data in U.S. dollars
| Financial Highlights |
|---|
| Sales |
61.27 Mil |
| Income |
-18.06 Mil |
| Net Profit Margin |
-29.48% |
| Return on Equity |
-16.82% |
| Debt/Equity Ratio |
2.21 |
|
| Revenue/Share |
0.66 |
| Earnings/Share |
-0.19 |
| Book Value/Share |
1.14 |
| Dividend Rate |
0.00 |
| Payout Ratio |
NA |
|
| Revenue - Quarterly Results (in Millions) |
|---|
| | FY (12/09) | FY (12/08) | FY (12/07) |
|---|
| 1st Qtr | 9.7 | 20.0 | 85.0 |
| 2nd Qtr | 13.0 | 20.4 | 65.9 |
| 3rd Qtr | 10.2 | 21.4 | 56.3 |
| 4th Qtr | NA | 28.4 | 65.8 |
| Total | 32.9 | 90.2 | 273.0 |
| Earnings Per Share - Quarterly Results |
|---|
| | FY (12/09) | FY (12/08) | FY (12/07) |
|---|
| 1st Qtr | -$0.34 | -$0.44 | -$0.28 |
| 2nd Qtr | -$0.35 | -$0.36 | -$0.30 |
| 3rd Qtr | -$0.33 | -$0.40 | -$0.20 |
| 4th Qtr | NA | $0.83 | $0.42 |
| Total | -$1.02 | -$0.37 | -$0.36 |
| Qtr. over Qtr. EPS Growth Rate |
| FY (12/09) | FY (12/08) | FY (12/07) |
|---|
| 1st Qtr | NA | NA | --- |
| 2nd Qtr | -3% | 18% | -7% |
| 3rd Qtr | 6% | -11% | 33% |
| 4th Qtr | NA | NA | NA |
| Yr. over Yr. EPS Growth Rate |
| FY (12/09) | FY (12/08) |
|---|
| 1st Qtr | 23% | -57% |
| 2nd Qtr | 3% | -20% |
| 3rd Qtr | 17% | -100% |
| 4th Qtr | NA | 98% |
advertisement
Recent News